Margaret Poulos, MD
Ophthalmology · Orlando, FLNPI 1477546851
Payments from drug & device makers
Across 437 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Alcon$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$785
- Kala Pharmaceuticals, Inc.$559
- Sun Pharmaceutical Industries Inc.$405
- Amgen$357
- plus $2K from 17 others
What the payments were for
- Food & beverage$7,615100%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 236 | $2,688 |
| Alcon | 34 | $1,010 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 41 | $785 |
| Kala Pharmaceuticals, Inc. | 19 | $559 |
| Sun Pharmaceutical Industries Inc. | 16 | $405 |
| Amgen(2 entities) | 11 | $357 |
| Aerie Pharmaceuticals, Inc. | 6 | $326 |
| Harrow Eye, LLC | 14 | $288 |
| Bausch & Lomb Americas Inc. | 21 | $286 |
| Rayner Intraocular Lenses Limited | 10 | $199 |
| Novartis | 10 | $185 |
| Ocular Therapeutix, Inc. | 1 | $117 |
| Mallinckrodt Hospital Products Inc. | 3 | $99 |
| Biotissue Holdings Inc. | 3 | $57 |
| Oyster Point Pharma, Inc. | 2 | $48 |
| Sight Sciences, Inc. | 2 | $38 |
| Eyevance Pharmaceuticals LLC | 2 | $34 |
| Thea Pharma Inc. | 1 | $33 |
| Tarsus Pharmaceuticals, Inc. | 1 | $33 |
| Dompe US, Inc. | 1 | $29 |
| Glaukos Corporation | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,635 in reported general payments places this provider in the 75th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 127 | $152,823 |
| LumiganBimatoprost | 217 | $133,506 |
| RocklatanNetarsudil Mesylat/Latanoprost | 91 | $59,168 |
| XiidraLifitegrast | 34 | $51,396 |
| XdemvyLotilaner | 20 | $38,282 |
| VyzultaLatanoprostene Bunod | 71 | $34,564 |
| Cyclosporine | 44 | $29,952 |
| VevyeCyclosporine | 25 | $29,153 |
| Alphagan PBrimonidine Tartrate | 50 | $25,733 |
| CombiganBrimonidine Tartrate/Timolol | 48 | $17,472 |
| Restasis MultidoseCyclosporine | 18 | $12,632 |
| Latanoprost | 993 | $12,356 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 80 | $12,070 |
| TafluprostTafluprost/Pf | 30 | $7,543 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 382 | $6,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan, Restasis Multidose | $2,688 | $342,165460 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $286 | $85,959105 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $326 | $59,16891 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $33 | $38,28220 claims |
| Harrow Eye, LLCVevye | $288 | $29,15325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Orlando
- Matthew CunninghamOrlando$2.9M
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.